Education
About Us
Working with TipRanks
Follow Us
Vertex Pharmaceuticals (VRTX)
NASDAQ:VRTX
VRTX Analyst Ratings
Strong Buy
21 Buy
2 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
VRTX Stock 12 Month Forecast
Average Price Target
$548.63
▲(18.95% Upside)
| Highest Price Target$625.00 | Average Price Target$548.63 | Lowest Price Target$466.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Truist Financial
Buy
―
Reiterated
02/13/26
H.C. Wainwright
$518
Buy
12.31%
Upside
Reiterated
02/13/26
Valuation and Risks. We are raising our PT to $518 from $478 as the JOURNAVX launch reaches a critical tipping point, validated by Q4 prescription volume matching the prior three quarters combined and the strategic 1Q26 unlock of all three national PBMs covering >200M lives. Our increased penetration assumptions are underpinned by robust KOL enthusiasm for suzetrigine’s 76–90% opioid-free success rates in real-world procedures, providing high visibility into management's guidance to triple annual scripts as they double the field force to 300 representatives.
William Blair
Buy
―
Reiterated
02/13/26
We continue to believe Alyftrek and follow-on CFTR correctors will maintain Vertex’s leadership position in CF ahead of competitor clinical data this year. Beyond CF, we view both Journavx and Casgevy as at relative inflection points as Journavx weans off its patient support program to enable more favorable gross-to-net pricing and Casgevy revenues remain volatile amid new patient uptake dynamics. Together these products are guided to do at least $500 million in revenue in 2026 (more than 185% year-over-year growth).
Needham
Hold
―
Reiterated
02/13/26
Evercore ISI
$530
Buy
14.91%
Upside
Reiterated
02/13/26
Morgan Stanley
$564→$570
Buy
23.58%
Upside
Reiterated
02/13/26
Stifel Nicolaus
$445→$466
Hold
1.03%
Upside
Reiterated
02/13/26
Oppenheimer
$540
Buy
17.08%
Upside
Upgraded
02/13/26
Cantor Fitzgerald
$485→$590
Buy
27.92%
Upside
Reiterated
02/13/26
Bank of America Securities
Buy
―
Reiterated
02/13/26
Bernstein
$572→$577
Buy
25.10%
Upside
Assigned
02/13/26
Scotiabank
$495→$558
Buy
20.98%
Upside
Reiterated
02/13/26
Citi
$575
Buy
24.66%
Upside
Reiterated
02/12/26
TD Cowen
$525
Buy
13.82%
Upside
Reiterated
02/12/26
RBC Capital
$546→$541
Buy
17.29%
Upside
Reiterated
02/12/26
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Truist Financial
Buy
―
Reiterated
02/13/26
H.C. Wainwright
$518
Buy
12.31%
Upside
Reiterated
02/13/26
Valuation and Risks. We are raising our PT to $518 from $478 as the JOURNAVX launch reaches a critical tipping point, validated by Q4 prescription volume matching the prior three quarters combined and the strategic 1Q26 unlock of all three national PBMs covering >200M lives. Our increased penetration assumptions are underpinned by robust KOL enthusiasm for suzetrigine’s 76–90% opioid-free success rates in real-world procedures, providing high visibility into management's guidance to triple annual scripts as they double the field force to 300 representatives.
William Blair
Buy
―
Reiterated
02/13/26
We continue to believe Alyftrek and follow-on CFTR correctors will maintain Vertex’s leadership position in CF ahead of competitor clinical data this year. Beyond CF, we view both Journavx and Casgevy as at relative inflection points as Journavx weans off its patient support program to enable more favorable gross-to-net pricing and Casgevy revenues remain volatile amid new patient uptake dynamics. Together these products are guided to do at least $500 million in revenue in 2026 (more than 185% year-over-year growth).
Needham
Hold
―
Reiterated
02/13/26
Evercore ISI
$530
Buy
14.91%
Upside
Reiterated
02/13/26
Morgan Stanley
$564→$570
Buy
23.58%
Upside
Reiterated
02/13/26
Stifel Nicolaus
$445→$466
Hold
1.03%
Upside
Reiterated
02/13/26
Oppenheimer
$540
Buy
17.08%
Upside
Upgraded
02/13/26
Cantor Fitzgerald
$485→$590
Buy
27.92%
Upside
Reiterated
02/13/26
Bank of America Securities
Buy
―
Reiterated
02/13/26
Bernstein
$572→$577
Buy
25.10%
Upside
Assigned
02/13/26
Scotiabank
$495→$558
Buy
20.98%
Upside
Reiterated
02/13/26
Citi
$575
Buy
24.66%
Upside
Reiterated
02/12/26
TD Cowen
$525
Buy
13.82%
Upside
Reiterated
02/12/26
RBC Capital
$546→$541
Buy
17.29%
Upside
Reiterated
02/12/26
Best Analysts Covering Vertex Pharmaceuticals
3 Months
xxx
Success Rate
21/29 ratings generated profit
Average Return
+7.07%
a xxx
rating ―
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 72.41% of your transactions generating a profit, with an average return of +7.07% per trade.
1 Year
Success Rate
15/18 ratings generated profit
Average Return
+11.57%
a rating ―
Copying Salveen Richter's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +11.57% per trade.
2 Years
xxx
Success Rate
33/37 ratings generated profit
Average Return
+19.54%
a xxx
rating ―
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 89.19% of your transactions generating a profit, with an average return of +19.54% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
VRTX Analyst Recommendation Trends
Rating
Oct 25
Nov 25
Dec 25
Jan 26
Feb 26
Strong Buy
2
0
0
0
0
Buy
35
37
41
47
46
Hold
17
17
15
13
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
54
54
56
60
49
Each month's total comprises the sum of three months' worth of ratings.
VRTX Financial Forecast
VRTX Stock Forecast FAQ
What is VRTX’s average 12-month price target, according to analysts?
Based on analyst ratings, Vertex Pharmaceuticals’s 12-month average price target is 548.63.
What is VRTX’s upside potential, based on the analysts’ average price target?
Vertex Pharmaceuticals has 18.95% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is VRTX a Buy, Sell or Hold?
Vertex Pharmaceuticals has a consensus rating of Strong Buy which is based on 21 buy ratings, 2 hold ratings and 0 sell ratings.
What is Vertex Pharmaceuticals’s price target?
The average price target for Vertex Pharmaceuticals is 548.63. This is based on 23 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $625.00 ,the lowest forecast is $466.00. The average price target represents 18.95% Increase from the current price of $461.24.
The highest analyst price target is $625.00 ,the lowest forecast is $466.00. The average price target represents 18.95% Increase from the current price of $461.24.
What do analysts say about Vertex Pharmaceuticals?
Vertex Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 23 Wall Streets Analysts.
How can I buy shares of VRTX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.